CINOVA: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer.

MLA

Boere, Ingrid, et al. “CINOVA: A Phase II Study of CPC634 (Nanoparticulate Docetaxel) in Patients with Platinum Resistant Recurrent Ovarian Cancer.” International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society, vol. 33, no. 8, Aug. 2023, pp. 1247–52. EBSCOhost, https://doi.org/10.1136/ijgc-2023-004308.

APA

Boere, I., Vergote, I., Hanssen, R., Jalving, M., Gennigens, C., Ottevanger, P., van de Wouw, Y. J., Rijcken, C. J. F., Mathijssen, R. H. J., & Ledermann, J. (2023). CINOVA: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society, 33(8), 1247–1252. https://doi.org/10.1136/ijgc-2023-004308

Chicago

Boere, Ingrid, Ignace Vergote, Rob Hanssen, Mathilde Jalving, Christine Gennigens, Petronella Ottevanger, Yes J van de Wouw, Cristianne J F Rijcken, Ron H J Mathijssen, and Jonathan Ledermann. 2023. “CINOVA: A Phase II Study of CPC634 (Nanoparticulate Docetaxel) in Patients with Platinum Resistant Recurrent Ovarian Cancer.” International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society 33 (8): 1247–52. doi:10.1136/ijgc-2023-004308.